Aquinox Pharmaceuticals (AQXP) Receiving Somewhat Critical News Coverage, Study Finds

Headlines about Aquinox Pharmaceuticals (NASDAQ:AQXP) have trended somewhat negative this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a coverage optimism score of -0.01 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.1776183624832 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

AQXP has been the subject of several analyst reports. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. BidaskClub cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, ValuEngine cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $22.25.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 4.75% during trading on Wednesday, hitting $13.23. 86,771 shares of the stock traded hands. Aquinox Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $19.97. The company’s market cap is $310.43 million. The stock has a 50-day moving average of $14.09 and a 200 day moving average of $14.30.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting analysts’ consensus estimates of ($0.59). On average, equities research analysts predict that Aquinox Pharmaceuticals will post ($2.15) EPS for the current fiscal year.

WARNING: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https:/

AQXP has been the subject of several analyst reports. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. BidaskClub cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, ValuEngine cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $22.25.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 4.75% during trading on Wednesday, hitting $13.23. 86,771 shares of the stock traded hands. Aquinox Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $19.97. The company’s market cap is $310.43 million. The stock has a 50-day moving average of $14.09 and a 200 day moving average of $14.30.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting analysts’ consensus estimates of ($0.59). On average, equities research analysts predict that Aquinox Pharmaceuticals will post ($2.15) EPS for the current fiscal year.

WARNING: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/18/aquinox-pharmaceuticals-aqxp-receiving-somewhat-critical-news-coverage-study-finds.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Insider Buying and Selling by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply